249 related articles for article (PubMed ID: 21603312)
1. Imaging of gastroenteropancreatic neuroendocrine tumors.
Tan EH; Tan CH
World J Clin Oncol; 2011 Jan; 2(1):28-43. PubMed ID: 21603312
[TBL] [Abstract][Full Text] [Related]
2. Somatostatin-receptor imaging of neuroendocrine gastroenteropancreatic tumors.
Scherübl H; Bäder M; Fett U; Hamm B; Schmidt-Gayk H; Koppenhagen K; Dop FJ; Riecken EO; Wiedenmann B
Gastroenterology; 1993 Dec; 105(6):1705-9. PubMed ID: 7902821
[TBL] [Abstract][Full Text] [Related]
3. [Significance of false-positive findings of somatostatin receptor scintigraphy in diagnosis of neuroendocrine tumors of the gastroenteropancreatic system].
Faiss S; Scherübl H; Bäder M; Fett U; Koppenhagen K; Wiedenmann B; Riecken EO
Z Gastroenterol; 1994 May; 32(5):243-6. PubMed ID: 7915450
[TBL] [Abstract][Full Text] [Related]
4. Somatostatin receptor scintigraphy in the diagnosis of neuroendocrine gastroenteropancreatic tumors.
Bäder M; Koppenhagen K
Recent Results Cancer Res; 1996; 142():137-62. PubMed ID: 8893340
[TBL] [Abstract][Full Text] [Related]
5. Prospective comparison of whole-body MRI with diffusion-weighted and conventional imaging for the follow-up of neuroendocrine tumors.
Minon M; Soriano C; Morland D; Walter T; Lepage C; Tabarin A; Deblock M; Rousset P; Barbe C; Hoeffel C; Cadiot G
Endocrine; 2020 Jan; 67(1):243-251. PubMed ID: 31564038
[TBL] [Abstract][Full Text] [Related]
6. Molecular imaging of gastroenteropancreatic neuroendocrine tumors.
Miederer M; Weber MM; Fottner C
Gastroenterol Clin North Am; 2010 Dec; 39(4):923-35. PubMed ID: 21093764
[TBL] [Abstract][Full Text] [Related]
7. [Contributions of nuclear medicine to the diagnosis and follow-up of gastroenteropancreatic neuroendocrine tumors].
Casanovas MM
Endocrinol Nutr; 2009 Sep; 56 Suppl 3():14-9. PubMed ID: 20542215
[TBL] [Abstract][Full Text] [Related]
8. An orthotopic model of pancreatic somatostatin receptor (SSTR)-positive tumors allows bimodal imaging studies using 3T MRI and animal PET-based molecular imaging of SSTR expression.
Stelter L; Amthauer H; Rexin A; Pinkernelle J; Schulz P; Michel R; Denecke T; Stiepani H; Hamm B; Wiedenmann B; Scholz A
Neuroendocrinology; 2008; 87(4):233-42. PubMed ID: 18025811
[TBL] [Abstract][Full Text] [Related]
9. Role of (111)In-DTPA-pentetreotide scintigraphy in accurate diagnosis of neuroendocrine gastroenteropancreatic tumors.
Ichijo T; Ishikawa M; Shimojo M; Tsubuku M; Tsuboi K; Miyachi Y
J Hepatobiliary Pancreat Surg; 2001; 8(5):473-8. PubMed ID: 11702259
[TBL] [Abstract][Full Text] [Related]
10. Nuclear medicine techniques for the imaging and treatment of neuroendocrine tumours.
Teunissen JJ; Kwekkeboom DJ; Valkema R; Krenning EP
Endocr Relat Cancer; 2011 Oct; 18 Suppl 1():S27-51. PubMed ID: 22005114
[TBL] [Abstract][Full Text] [Related]
11. Functional imaging of neuroendocrine tumors: a head-to-head comparison of somatostatin receptor scintigraphy, 123I-MIBG scintigraphy, and 18F-FDG PET.
Binderup T; Knigge U; Loft A; Mortensen J; Pfeifer A; Federspiel B; Hansen CP; Højgaard L; Kjaer A
J Nucl Med; 2010 May; 51(5):704-12. PubMed ID: 20395333
[TBL] [Abstract][Full Text] [Related]
12. The value of somatostatin-receptor scintigraphy in newly diagnosed endocrine gastroenteropancreatic tumors.
Kisker O; Bartsch D; Weinel RJ; Joseph K; Welcke UH; Zaraca F; Rothmund M
J Am Coll Surg; 1997 May; 184(5):487-92. PubMed ID: 9145069
[TBL] [Abstract][Full Text] [Related]
13. Clinical Usefulness of Somatostatin Receptor Scintigraphy in Japanese Patients with Gastroenteropancreatic Neuroendocrine Tumors.
Hasegawa S; Kobayashi N; Tokuhisa M; Goto A; Takano S; Takada Y; Kaneta T; Mori R; Matsuyama R; Endo I; Yamanaka S; Nakajima A; Inoue T; Ichikawa Y
Digestion; 2017; 96(1):13-20. PubMed ID: 28609761
[TBL] [Abstract][Full Text] [Related]
14. Gastroenteropancreatic neuroendocrine tumors: role of imaging in diagnosis and management.
Sahani DV; Bonaffini PA; Fernández-Del Castillo C; Blake MA
Radiology; 2013 Jan; 266(1):38-61. PubMed ID: 23264526
[TBL] [Abstract][Full Text] [Related]
15. Role of positron emission tomography in thyroid and neuroendocrine tumors.
Treglia G; Kroiss AS; Piccardo A; Lococo F; Santhanam P; Imperiale A
Minerva Endocrinol; 2018 Sep; 43(3):341-355. PubMed ID: 28949122
[TBL] [Abstract][Full Text] [Related]
16. Significance of a Single-Time-Point Somatostatin Receptor SPECT/Multiphase CT Protocol in the Diagnostic Work-up of Gastroenteropancreatic Neuroendocrine Neoplasms.
Ruf J; von Wedel F; Furth C; Denecke T; Stelter L; Steffen IG; Schütte K; Arend J; Ulrich G; Klose S; Bornschein J; Apostolova I; Amthauer H
J Nucl Med; 2016 Feb; 57(2):180-5. PubMed ID: 26609177
[TBL] [Abstract][Full Text] [Related]
17. PRRT in high-grade gastroenteropancreatic neuroendocrine neoplasms (WHO G3).
Sorbye H; Kong G; Grozinsky-Glasberg S
Endocr Relat Cancer; 2020 Mar; 27(3):R67-R77. PubMed ID: 31846429
[TBL] [Abstract][Full Text] [Related]
18. Incremental diagnostic value and impact on patient management of somatostatin receptor scintigraphy with indium-111-pentetreotide in gastroenteropancreatic neuroendocrine tumors.
Usmani S; Khan HA; Abdulla M; Ahmed N; abu Huda F; Marafi F; al Kandari F; al Mohannadi S; al Nafisi N
Med Princ Pract; 2011; 20(4):356-61. PubMed ID: 21576997
[TBL] [Abstract][Full Text] [Related]
19. [Contemporary nuclear medicine diagnostics of neuroendocrine tumors].
Srp Arh Celok Lek; 2015; 143(1-2):108-15. PubMed ID: 25845263
[TBL] [Abstract][Full Text] [Related]
20. Imaging of neuroendocrine tumors.
Rufini V; Calcagni ML; Baum RP
Semin Nucl Med; 2006 Jul; 36(3):228-47. PubMed ID: 16762613
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
